Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants

Molecular Pharmacology

Volumn 68, Issue 2, 2005, Pages 383-392

  Koukouritaki, Sevasti B ^a   Poch, Mark T ^a   Cabacungan, Erwin T ^a   McCarver, D Gail ^a   Hines, Ronald N ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE; DNA; FLAVIN CONTAINING MONOOXYGENASE 3; FLAVINE ADENINE NUCLEOTIDE; GUANINE NUCLEOTIDE; LUCIFERASE; PYRIMIDINE NUCLEOTIDE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

AFRICAN AMERICAN; ARTICLE; BINDING AFFINITY; CAUCASIAN; CELL STRAIN HEPG2; CONTROLLED STUDY; DNA SEQUENCE; EXON; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENETIC VARIABILITY; HAPLOTYPE; HISPANIC; HUMAN; HUMAN CELL; INTRON; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; SAMPLE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; HAPLOTYPES; HUMANS; MOLECULAR SEQUENCE DATA; OXYGENASES; PENAEIDAE; POLYMORPHISM, SINGLE NUCLEOTIDE; VARIATION (GENETICS);

EID: 23044469807     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.105.012062     Document Type: Article

References (40)

1. Basarab T, Ashton GHS, Menage HD, and McGrath JA (1999) Sequence variations in the flavin-containing monooxygenase 3 gene (FMO3) in fish odour syndrome. Br J Dermatol 140:164-167.
2. Boucher PD, Ruch RJ, and Hines RN (1993) Specific nuclear protein binding to a negative regulatory element on the human CYP1A1 gene. J Biol Chem 268:17384-17391.
3. Cashman JR (2002) Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism. Pharmacogenomics 3:325-339.
4. Cashman JR (2004) The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development. Drug Discov Today 9:574-581.
5. Cashman JR, Bi YA, Lin J, Youil R, Knight M, Forrest S, and Treacy E (1997) Human flavin-containing monooxygenase form 3: cDNA expression of the enzymes containing amino acid substitutions observed in individuals with trimethylaminuria. Chem Res Toxicol 10:837-841.
6. Collins FS, Brooks LD, and Chakravarti A (1998) A DNA polymorphism discovery resource for research on human genetic variation. Genome Res 8:1229-1231.
7. Dolphin CT, Janmohamed A, Smith RL, Shephard EA, and Phillips IR (2000) Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FMO3) gene in patients with fish-odour syndrome. Pharmacogenetics 10:799-807.
8. Fairbrother WG, Yeh R-F, Sharp PA, and Burge CB (2002) Predictive identification of exonic splicing enhancers in human genes. Science (Wash DC) 297:1007-1013.
9. Forrest SM, Knight M, Akerman BR, Cashman JR, and Treacy EP (2001) A novel deletion in the flavin-containing monooxygenase gene (FMO3) in a Greek patient with trimethylaminuria. Pharmacogenetics 11:169-174.
10. Garnier J, Osguthorpe DJ, and Robson B (1978) Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. J Mol Biol 120:97-120.
11. Hernandez D, Janmohamed A, Chandan P, Phillips IR, and Shephard EA (2004) Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 14:117-130.
12. Hines RN, Hopp KA, Franco J, Saeian K, and Begun FP (2002) Alternative processing of the human hepatic FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase. Mol Pharmacol 62:320-325.
13. Hines RN, Luo Z, Hopp KA, Cabacungan ET, Koukouritaki SB, and McCarver DG (2003) Genetic variability at the human FMO1 locus: significance of a yin yang 1 element polymorphism (FMO1*6). J Pharmacol Exp Ther 306:1210-1218.
14. Hoogendoorn B, Coleman SL, Guy CA, Smith K, Bowen T, Buckland PR, and O'Donovan MC (2003) Functional analysis of human promoter polymorphisms. Hum Mol Genet 12:2249-2254.
15. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, and Hines RN (2002) Human hepatic flavin-containing monooxygenase 1 (FMO1) and 3 (FMO3) developmental expression. Pediatric Res 51:236-243.
16. Krueger SK and Williams DE (2005) Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 106:357-387.
17. Kyte J and Doolittle RF (1982) A simple method for displaying the hydropathic character of a protein. J Mol Biol 157:105-132.
18. Lattard V, Zhang J, and Cashman JR (2004) Alternative processing events in human FMO genes. Mol Pharmacol 65:1517-1525.
19. Lattard V, Zhang J, Tran Q, Furnes B, Schlenk D, and Cashman JR (2003) Two new polymorphisms of the fmo3 gene in Caucasian and African-American populations: comparative genetic and functional studies. Drug Metab Dispos 31:854-860.
20. Lindblad-Toh K, Winchester E, Daly MJ, Wang DG, Hirschhorn JN, Laviolette J-P, Ardlie K, Reich DE, Robinson E, Sklar P, et al. (2000) Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse. Nat Genet 24:381-386.
21. Liu H-X, Chew SL, Cartegni L, Zhang MQ, and Krainer AR (2000) Exonic splicing enhancer motif recognized by human SC35 under splicing conditions. Mol Cell Biol 20:1063-1071.
22. Liu H-X, Zhang M, and Krainer AR (1998) Identification of functional exonic splicing enhancer motifs recognized by individual sr proteins. Genes Dev 12:1998-2012.
23. Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV, et al. (2003) TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 31:374-378.
24. McCarver DG, Thomasson H, Martier SS, Sokol RJ, and Li T-K (1997) Alcohol dehydrogenase-2*3 allele protects against alcohol-related birth defects among African Americans. J Pharmacol Exp Ther 283:1095-1101.
25. Overby LH, Carver GC, and Philpot RM (1997) Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact 106:29-45.
26. Park C-S, Kang J-H, Chung W-G, Yi H-G, Pie J-E, Park D-K, Hines RN, McCarver DG, and Cha Y-N (2002) Ethnic differences in allelic frequency for two flavincontaining monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities. Pharmacogenetics 12:77-80.
27. Pastinen T and Hudson TJ (2004) cis-Acting regulatory variation in the human genome. Science (Wash DC) 306:647-650.
28. Rogan PK, Faux BM, and Schneider TD (1998) Information analysis of human splice site mutations. Hum Mutat 12:153-171.
29. Rogan PK, Svojanovsky S, and Leeder JS (2003) Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. Pharmacogenetics 13:1-12.
30. Shehin-Johnson SE, Williams DE, Larsen-Su S, Stresser DM, and Hines RN (1995) Tissue-specific expression of flavin-containing monooxygenase (FMO) forms 1 and 2 in the rabbit. J Pharmacol Exp Ther 272:1293-1299.
31. Stephens M and Donnelly P (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162-1169.
32. Stephens M, Smith NJ, and Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989.
33. Treacy EP, Akerman BR, Chow LML, Youil R, Bibeau C, Lin J, Bruce AG, Knight M, Danks DM, Cashman JR, et al. (1998) Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum Mol Genet 7:839-845.
34. Whetstine JR, Yueh M-F, Hopp KA, McCarver DG, Williams DE, Park C-S, Kang Y-N, Cha Y-N, Dolphin CT, Shephard EA, et al. (2000) Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans. Toxicol Appl Pharmacol 168:216-224.
35. Wrighton SA, Brian WR, Sari M-A, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, and Vandenbranden M (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207-213.
36. Yeung CK, Lang DH, Thummel KE, and Rettie AE (2000) Immunoquantitation of FMO1 in human liver, kidney and intestine. Drug Metab Dispos 28:1107-1111.
37. Yu A, Kneller BM, Rettie AE, and Haining RL (2002) Expression, purification, biochemical characterization and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic forms. J Pharmacol Exp Ther 303:1291-1300.
38. Zheng Y-M, Henne KR, Charmley P, Kim RB, McCarver DG, Cabacungan ET, Hines RN, and Rettie AE (2003) Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis. Toxicol Appl Pharmacol 186:119-126.
39. Ziegler DM (2002) An overview of the mechanism, substrate specificities and structure of FMOs. Drug Metab Rev 34:503-511.
40. Zschocke J, Kohlmüeller D, Quak E, Meissner T, Hoffmann GF, and Mayatepek E (1999) Mild trimethylaminuria caused by common variants in FMO3 gene. Lancet 354:834-835.